Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure

Román A. Barraza, Jay W. McLaren, Eric M. Poeschla

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in prostaglandin (PG) biosynthesis. In the eye, loss of COX-2 expression in aqueous humor-secreting cells has been associated with primary open-angle glaucoma (POAG). Reduction of intraocular pressure (IOP) is the main treatment goal in this disease. We used lentiviral vectors to stably express COX-2 and other PG biosynthesis and response transgenes in the ciliary body epithelium and trabecular meshwork (TM), the ocular suborgans that produce aqueous humor and regulate its outflow, respectively. We show that robust ectopic COX-2 expression and PG production require COX-2 complementary DNA (cDNA) sequence optimization. When COX-2 expression was coupled with a similarly optimized synthetic PGF 2α receptor transgene to enable downstream signaling, gene therapy produced substantial and sustained reductions in IOP in a large animal model, the domestic cat. This study provides the first gene therapy for correcting the main cause of glaucoma.

Original languageEnglish (US)
Pages (from-to)491-501
Number of pages11
JournalMolecular Therapy
Volume18
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Cyclooxygenase 2
Intraocular Pressure
Genetic Therapy
Prostaglandins
Aqueous Humor
Transgenes
Trabecular Meshwork
Ciliary Body
Glaucoma
Cats
Epithelium
Animal Models
Complementary DNA
Enzymes

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure. / Barraza, Román A.; McLaren, Jay W.; Poeschla, Eric M.

In: Molecular Therapy, Vol. 18, No. 3, 03.2010, p. 491-501.

Research output: Contribution to journalArticle

Barraza, Román A. ; McLaren, Jay W. ; Poeschla, Eric M. / Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure. In: Molecular Therapy. 2010 ; Vol. 18, No. 3. pp. 491-501.
@article{52ec193a9a3e49af8bffaac91dbc8f92,
title = "Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure",
abstract = "Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in prostaglandin (PG) biosynthesis. In the eye, loss of COX-2 expression in aqueous humor-secreting cells has been associated with primary open-angle glaucoma (POAG). Reduction of intraocular pressure (IOP) is the main treatment goal in this disease. We used lentiviral vectors to stably express COX-2 and other PG biosynthesis and response transgenes in the ciliary body epithelium and trabecular meshwork (TM), the ocular suborgans that produce aqueous humor and regulate its outflow, respectively. We show that robust ectopic COX-2 expression and PG production require COX-2 complementary DNA (cDNA) sequence optimization. When COX-2 expression was coupled with a similarly optimized synthetic PGF 2α receptor transgene to enable downstream signaling, gene therapy produced substantial and sustained reductions in IOP in a large animal model, the domestic cat. This study provides the first gene therapy for correcting the main cause of glaucoma.",
author = "Barraza, {Rom{\'a}n A.} and McLaren, {Jay W.} and Poeschla, {Eric M.}",
year = "2010",
month = "3",
doi = "10.1038/mt.2009.278",
language = "English (US)",
volume = "18",
pages = "491--501",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure

AU - Barraza, Román A.

AU - McLaren, Jay W.

AU - Poeschla, Eric M.

PY - 2010/3

Y1 - 2010/3

N2 - Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in prostaglandin (PG) biosynthesis. In the eye, loss of COX-2 expression in aqueous humor-secreting cells has been associated with primary open-angle glaucoma (POAG). Reduction of intraocular pressure (IOP) is the main treatment goal in this disease. We used lentiviral vectors to stably express COX-2 and other PG biosynthesis and response transgenes in the ciliary body epithelium and trabecular meshwork (TM), the ocular suborgans that produce aqueous humor and regulate its outflow, respectively. We show that robust ectopic COX-2 expression and PG production require COX-2 complementary DNA (cDNA) sequence optimization. When COX-2 expression was coupled with a similarly optimized synthetic PGF 2α receptor transgene to enable downstream signaling, gene therapy produced substantial and sustained reductions in IOP in a large animal model, the domestic cat. This study provides the first gene therapy for correcting the main cause of glaucoma.

AB - Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in prostaglandin (PG) biosynthesis. In the eye, loss of COX-2 expression in aqueous humor-secreting cells has been associated with primary open-angle glaucoma (POAG). Reduction of intraocular pressure (IOP) is the main treatment goal in this disease. We used lentiviral vectors to stably express COX-2 and other PG biosynthesis and response transgenes in the ciliary body epithelium and trabecular meshwork (TM), the ocular suborgans that produce aqueous humor and regulate its outflow, respectively. We show that robust ectopic COX-2 expression and PG production require COX-2 complementary DNA (cDNA) sequence optimization. When COX-2 expression was coupled with a similarly optimized synthetic PGF 2α receptor transgene to enable downstream signaling, gene therapy produced substantial and sustained reductions in IOP in a large animal model, the domestic cat. This study provides the first gene therapy for correcting the main cause of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=77649275883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649275883&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.278

DO - 10.1038/mt.2009.278

M3 - Article

C2 - 19953083

AN - SCOPUS:77649275883

VL - 18

SP - 491

EP - 501

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -